Matrix Asset Advisors Inc. NY Has $11.84 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Matrix Asset Advisors Inc. NY cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 120,206 shares of the medical equipment provider’s stock after selling 6,717 shares during the quarter. Matrix Asset Advisors Inc. NY owned about 0.06% of Zimmer Biomet worth $11,840,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Zimmer Biomet during the second quarter worth approximately $37,000. CoreFirst Bank & Trust bought a new stake in Zimmer Biomet in the second quarter worth approximately $38,000. Hilltop National Bank acquired a new position in Zimmer Biomet in the second quarter valued at approximately $42,000. Finally, True Wealth Design LLC boosted its holdings in shares of Zimmer Biomet by 875.0% during the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 420 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $89.25 on Monday. The business has a fifty day simple moving average of $94.96 and a two-hundred day simple moving average of $96.71. Zimmer Biomet Holdings, Inc. has a 1 year low of $85.33 and a 1 year high of $114.44. The company has a market capitalization of $17.69 billion, a P/E ratio of 22.09, a P/E/G ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZBH. Baird R W lowered shares of Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 16th. Citigroup decreased their price target on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Finally, Royal Bank Of Canada decreased their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $107.50.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.